GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Cyclically Adjusted FCF per Share

Sunshine Biopharma (Sunshine Biopharma) Cyclically Adjusted FCF per Share : $-2,026.62 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sunshine Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-647.500. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2,026.62 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sunshine Biopharma was 20.30% per year. The lowest was 10.40% per year. And the median was 17.85% per year.

As of today (2024-06-07), Sunshine Biopharma's current stock price is $0.5579. Sunshine Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-2,026.62. Sunshine Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Sunshine Biopharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Sunshine Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Cyclically Adjusted FCF per Share Chart

Sunshine Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,634.53 -2,760.75 -2,329.30 -2,071.24 -1,987.67

Sunshine Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,179.20 -2,123.49 -2,062.02 -1,987.67 -2,026.62

Competitive Comparison of Sunshine Biopharma's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Cyclically Adjusted Price-to-FCF falls into.



Sunshine Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sunshine Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-647.5/126.2576*126.2576
=-647.500

Current CPI (Mar. 2024) = 126.2576.

Sunshine Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 0.000 98.367 0.000
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 -1,080.000 102.634 -1,328.591
201706 -780.000 103.029 -955.859
201709 -1,345.455 103.345 -1,643.760
201712 -1,900.000 103.345 -2,321.255
201803 -1,572.727 105.004 -1,891.059
201806 -625.000 105.557 -747.568
201809 -1,257.143 105.636 -1,502.555
201812 -535.000 105.399 -640.877
201903 -1,114.286 106.979 -1,315.088
201906 -213.636 107.690 -250.470
201909 -87.000 107.611 -102.075
201912 -64.000 107.769 -74.979
202003 -15.500 107.927 -18.133
202006 -10.250 108.401 -11.938
202009 -8.643 108.164 -10.089
202012 -24.941 108.559 -29.007
202103 -13.500 110.298 -15.453
202106 -25.792 111.720 -29.148
202109 -24.040 112.905 -26.883
202112 -8.667 113.774 -9.618
202203 -24.604 117.646 -26.405
202206 -3.633 120.806 -3.797
202209 -5.947 120.648 -6.224
202212 -10.031 120.964 -10.470
202303 -1,014.000 122.702 -1,043.382
202306 -16.031 124.203 -16.296
202309 -1.825 125.230 -1.840
202312 -12.580 125.072 -12.699
202403 -647.500 126.258 -647.500

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Sunshine Biopharma  (NAS:SBFM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sunshine Biopharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma (Sunshine Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3

Sunshine Biopharma (Sunshine Biopharma) Headlines

From GuruFocus

Sunshine Biopharma Initiates COVID-19 Treatment Mice Study

By ACCESSWIRE ACCESSWIRE 02-10-2021

Sunshine Biopharma's Annual Letter to Shareholders

By Value_Insider Value_Insider 12-20-2022